Company: MIRA
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001183
Chunk: 225

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 1C
Chunk 225
---
 of this Report on Form 10-K, which is incorporated
into this item by reference.

Item
3. Legal Proceedings.

None

Item
4. Mine Safety Disclosures.

Not
applicable.

PART
II

Item
5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Market
Information

Our
common stock has been public traded on The Nasdaq Capital Market under the symbol “MIRA” since August 3, 2023. Prior to
that date, there was no public trading market for our common stock.

57

Holders
of Common Stock

As
of March 28, 2025, we had approximately 55 holders of  record of our common stock. No cash dividends have been paid on the common
stock to date. We currently intend to retain earnings for further business development and do not expect to pay cash dividends in the
foreseeable future.

Securities
Authorized for Issuance Under Equity Compensation Plans

See
Item 12. - Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Unregistered
Sales of Equity Securities and Use of Proceeds

None

Issuer
Purchases of Equity Securities

None

Item
6. Reserved

MANAGEMENT’S
DISCUSSION AND ANALYSIS OF

FINANCIAL
CONDITION AND RESULTS OF OPERATIONS

The
following discussion and analysis provide information which our management believes is relevant to an assessment and understanding of
our results of operations and financial condition. You should read the following discussion and analysis of our results of operations
and financial condition together with our financial statements and related notes and other information included elsewhere in this Report.

In
addition to historical financial information, this discussion contains forward-looking statements based upon our current expectations
that involve risks and uncertainties. Our actual results could differ materially from such forward-looking statements as a result of
various factors, including those set forth under “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements”
included elsewhere in this Report. Additionally, our historical results are not necessarily indicative of the results that may be expected
for any period in the future.

Overview

MIRA
Pharmaceuticals, Inc. (NASDAQ: MIRA) is a clinical-stage pharmaceutical development company advancing two neuroscience programs targeting
neurologic and neuropsychiatric disorders. The company holds exclusive rights in the U.S., Canada, and Mexico for Ketamir-2 and MIRA-